• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Specific therapeutic attempts in experimental and clinical type-I diabetes.

作者信息

Federlin K, Becker F

机构信息

IIIrd Medical Clinic and Policlinic, Justus-Liebig-University, Giessen, FRG.

出版信息

Klin Wochenschr. 1990;68 Suppl 21:38-43.

PMID:2198389
Abstract

The morphological basis of type-I diabetes is the destruction of the islets of Langerhans by an inflammatory process. Immunosuppressive and immunomodulatory mechanisms can prevent diabetes in NOD-mice and BB-rats when given before onset of the disease. In man at the time of diagnosis of diabetes insulitis has progressed already to a loss of more than 80% of the Beta-cells. Several immunosuppressive drugs and immunobiological regimen may influence the course of the disease only in the sense of a temporary remission. Cyclosporine-A was the most effective drug, but can not be recommended for general use at present time because of side effects on the kidney at least when given in higher doses. Whether minimizing the effective dose will be equally effective remains open. Other drugs as ciamexone which seems to be safer have to be taken into account for further studies. Suppression of insulitis most probably will be more successful when the treatment starts at an earlier phase i.e. before onset of the disease. The criteria at what time this may be justified have to be elaborated.

摘要

相似文献

1
Specific therapeutic attempts in experimental and clinical type-I diabetes.
Klin Wochenschr. 1990;68 Suppl 21:38-43.
2
[Principles of immunotherapy in insulin-dependent diabetes mellitus].[胰岛素依赖型糖尿病的免疫治疗原则]
Wien Klin Wochenschr. 1988 Jun 24;100(13):435-42.
3
The NOD mouse as a model of type I diabetes.非肥胖糖尿病(NOD)小鼠作为I型糖尿病的模型。
Crit Rev Immunol. 1987;8(1):49-81.
4
Autoimmune disorders in diabetes.糖尿病中的自身免疫性疾病。
Adv Nephrol Necker Hosp. 1986;15:281-305.
5
Prevention of diabetes and induction of non-specific suppressor cell activity in the BB rat by an immunomodulatory azaspirane, SK&F 106610.免疫调节氮杂环丙烷SK&F 106610对BB大鼠糖尿病的预防及非特异性抑制细胞活性的诱导作用
J Autoimmun. 1993 Feb;6(1):39-49. doi: 10.1006/jaut.1993.1004.
6
[Immunology of type-1 diabetes. The initial stages in a causal therapy].[1型糖尿病的免疫学。因果治疗的初始阶段]
Dtsch Med Wochenschr. 1986 Apr 11;111(15):593-6. doi: 10.1055/s-2008-1068497.
7
AEB-071 has minimal impact on onset of autoimmune diabetes in NOD mice.AEB - 071对非肥胖糖尿病(NOD)小鼠自身免疫性糖尿病的发病影响极小。
Autoimmunity. 2009 Mar;42(3):242-8. doi: 10.1080/08916930802587950.
8
Early intervention in insulin-dependent diabetes mellitus.胰岛素依赖型糖尿病的早期干预
Curr Probl Clin Biochem. 1983;12:108-18.
9
[Will type I diabetes mellitus be treated with immunosuppressive drugs in the future?].[未来1型糖尿病会用免疫抑制药物治疗吗?]
Ther Umsch. 1993 Feb;50(2):114-8.
10
The role of immunotherapy in type I diabetes mellitus.免疫疗法在I型糖尿病中的作用。
West J Med. 1987 Mar;146(3):337-43.